Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 49

Results For "disease"

2348 News Found

Datroway approved in the US for patients with previously treated metastatic HR-positive breast cancer
Drug Approval | January 18, 2025

Datroway approved in the US for patients with previously treated metastatic HR-positive breast cancer

Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030


Calquence combination approved in US for untreated mantle cell lymphoma
Drug Approval | January 18, 2025

Calquence combination approved in US for untreated mantle cell lymphoma

Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone


Need for inter-sectoral collaboration, enhanced research, and innovative practices to address growing burden of NCDs: Health Secretary Srivastava
Public Health | January 15, 2025

Need for inter-sectoral collaboration, enhanced research, and innovative practices to address growing burden of NCDs: Health Secretary Srivastava

The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs


Bayer’s pharma growth strategy progressing well as pipeline advances
News | January 15, 2025

Bayer’s pharma growth strategy progressing well as pipeline advances

Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid


Odisha to implement AB PM-JAY scheme
News | January 14, 2025

Odisha to implement AB PM-JAY scheme

The scheme is fully digitized and covers approximately 45% of India's population


Pfizer’s Sasanlimab in combination with BCG improves survival in patients with bladder cancer
Clinical Trials | January 13, 2025

Pfizer’s Sasanlimab in combination with BCG improves survival in patients with bladder cancer

If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population


Zaynich achieves over 97% efficacy in clinical study for meropenem-resistant gram-negative pathogens
Clinical Trials | January 13, 2025

Zaynich achieves over 97% efficacy in clinical study for meropenem-resistant gram-negative pathogens

The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure


Genome India Project marks a defining moment for country's biotechnology landscape: Modi
Policy | January 11, 2025

Genome India Project marks a defining moment for country's biotechnology landscape: Modi

Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research


Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies
Clinical Trials | January 10, 2025

Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies

QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients


Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107
Clinical Trials | January 09, 2025

Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107

The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs